Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies
Authors:
- 12 April 2000
- journal article
- clinical trial
- Published by Elsevier in Journal of Chromatography B: Biomedical Sciences and Applications
- Vol. 740 (2) , 159-168
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.Journal of Clinical Oncology, 1997
- Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.Journal of Clinical Oncology, 1996
- Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecanCancer Chemotherapy and Pharmacology, 1995
- Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urineCancer Chemotherapy and Pharmacology, 1995
- A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38Japanese Journal of Cancer Research, 1995
- CPT-11: Population Pharmacokinetic Model and Estimation of Pharmacokinetics Using the Bayesian Method in Patients with Lung CancerJapanese Journal of Cancer Research, 1994
- Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.Journal of Clinical Oncology, 1994
- Phase I and pharmacokinetic trial of weekly CPT-11.Journal of Clinical Oncology, 1993
- CPT-11 Converting Enzyme from Rat Serum: Purification and Some Properties.Journal of Pharmacobio-Dynamics, 1991
- On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complexBiochemistry, 1989